We are actively communicating the latest around Johnson & Johnson’s multi-pronged response to the ongoing COVID-19 crisis. Please see below for recent announcements, leadership quotes available for media use and a library of downloadable images, headshots and logos.
To access the broader J&J Media Center, click here.
It’s an honor to support those on the frontlines of care to help patients when they are at their most vulnerable. We are committed to partnering with healthcare systems, surgeons and patients as we navigate the new normal in elective surgeries during the COVID-19 pandemic and ensure people everywhere are getting the treatment they need.
While we focus on stopping COVID-19 now we must also keep one eye to the future and ensure we are learning from this experience and applying those lessons. Effective, sustained and coordinated advocacy about the policy and system reforms necessary to prevent future outbreaks will be critical to ensure this happens. That’s why the world needs the Pandemic Action Network.
We greatly value the U.S. government’s confidence and support for our R&D efforts. Johnson & Johnson’s global team of experts has ramped up our research and development processes to unprecedented levels, and our teams are working tirelessly alongside BARDA, scientific partners, and global health authorities.
We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January. We are moving on an accelerated timeline toward Phase 1 human clinical trials at the latest by September 2020 and, supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021.
It is critical to work with the best scientific minds as we look to rapidly identify and develop solutions to the COVID-19 outbreak. By mobilizing our collective resources, we believe we can leverage the top science and cutting-edge capabilities to respond to this pandemic.
The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.
Those at the frontlines are our colleagues, family members, customers, and partners; so we join the millions around the world who put them front and center right now, to support them as they provide care amidst COVID-19. We are proud to focus our pandemic response donations on the needs of frontline health workers and make a $50M commitment in addition to the $250M, 10-year commitment made earlier this year through the Johnson & Johnson Center for Health Worker Innovation.
One aspect that is critically important is open access to data sharing so that we all learn from each other…the only competitor here is the virus.
We recognize the urgent need for solutions to address this urgent global health crisis. In response to the coronavirus outbreak, we are mobilizing all available resources and working with our global partners to help combat this virus.
As part of the effort to help combat the coronavirus outbreak, we have initiated efforts to broadly collaborate with others to screen a library of antiviral molecules, in order to identify a solution that could contribute to providing immediate relief to the current coronavirus outbreak.